Skip to main content

Table 4 Effects of respiratory function tests (values dichotomized) on the change in VC in pirfenidone and placebo groups

From: Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

Group

Parameter

Estimate

S.E.

t-value

p-value

Pirfenidone

Intercept

-0.0857

0.0523

-1.64

0.1039

(n = 155)

The lowest SpO2: <90 vs ≥90

-0.0090

0.0381

-0.24

0.8133

 

%VC: <70 vs ≥70

0.1447

0.0386

3.75

0.0002

 

PaO2: <70 vs ≥70

-0.1111

0.0558

-1.99

0.0483

Placebo

Intercept

-0.1196

0.0923

-1.30

0.1982

(n = 103)

The lowest SpO2: <90 vs ≥90

0.0628

0.0566

1.11

0.2701

 

%VC: <70 vs ≥70

0.0302

0.0585

0.52

0.6067

 

PaO2: <70 vs ≥70

-0.0977

0.0878

-1.11

0.2685